Dicyclomine

Revision as of 16:53, 17 September 2014 by Vignesh Ponnusamy (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Dicyclomine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: {[VP

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dicyclomine is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Dicyclomine FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Dicyclomine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

There is limited information regarding Dicyclomine Contraindications in the drug label.

Warnings

There is limited information regarding Dicyclomine Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Dicyclomine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Dicyclomine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Dicyclomine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Dicyclomine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dicyclomine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dicyclomine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dicyclomine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Dicyclomine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Dicyclomine in geriatric settings.

Gender

There is no FDA guidance on the use of Dicyclomine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dicyclomine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dicyclomine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dicyclomine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dicyclomine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dicyclomine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Dicyclomine Administration in the drug label.

Monitoring

There is limited information regarding Dicyclomine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Dicyclomine and IV administrations.

Overdosage

There is limited information regarding Dicyclomine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Dicyclomine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Dicyclomine Mechanism of Action in the drug label.

Structure

There is limited information regarding Dicyclomine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Dicyclomine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Dicyclomine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Dicyclomine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Dicyclomine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Dicyclomine How Supplied in the drug label.

Storage

There is limited information regarding Dicyclomine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dicyclomine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dicyclomine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Dicyclomine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Dicyclomine interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Dicyclomine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Dicyclomine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.


|genericName=

Dicyclomine

|aOrAn=

an

|drugClass=

antispasmodic and anticholinergic agent

|indication=

functional bowel/irritable bowel syndrome

|hasBlackBoxWarning=

|adverseReactions=

dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness


|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

  • Content


|fdaLIADAdult=

Irritable Bowel Syndrome
  • Dosing Information
  • Oral Dosage and Administration in Adults
  • The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.

If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.

  • Intramuscular Dosage and Administration in Adults
  • BENTYL Intramuscular Injection must be administered via intramuscular route only. Do not administer by an other route. The recommended intramuscular dose is 10 mg to 20 mg four times a day. [see Clinical Pharmacology (12)]

The intramuscular injection is to be used only for 1 or 2 days when the patient cannot take oral medication.

  • Intramuscular injection is about twice as bioavailable as oral dosage forms.
  • Preparation for Intramuscular Administration
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • Aspirate the syringe before injecting to avoid intravascular injection, since thrombosis may occur if the drug is inadvertently injected intravascularly.


|offLabelAdultGuideSupport=

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dicyclomine in adult patients.


|offLabelAdultNoGuideSupport=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dicyclomine in adult patients.


|fdaLIADPed=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Dicyclomine in pediatric patients.


|offLabelPedGuideSupport=

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dicyclomine in pediatric patients.


|offLabelPedNoGuideSupport=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dicyclomine in pediatric patients.


|contraindications=

  • BENTYL is contraindicated in infants less than 6 months of age, nursing mothers], and in patients with:


|warnings=

Precautions

  • Inadvertent Intravenous Administration
  • BENTYL solution is for intramuscular administration only. Do not administer by any other route. Inadvertent intravenous administration may result in thrombosis, thrombophlebitis and injection site reactions such as pain, edema, skin color change, and reflex sympathetic dystrophy syndrome [see Adverse Reactions (6.2)].
  • Cardiovascular Conditions
  • Dicyclomine hydrochloride needs to be used with caution in conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. Investigate any tachycardia before administration of dicyclomine hydrochloride. Care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension [see Adverse Reactions (6.3)].
  • Peripheral and Central Nervous System
  • The peripheral effects of dicyclomine hydrochloride are a consequence of their inhibitory effect on muscarinic receptors of the autonomic nervous system. They include dryness of the mouth with difficulty in swallowing and talking, thirst, reduced bronchial secretions, dilatation of the pupils (mydriasis) with loss of accommodation (cycloplegia) and photophobia, flushing and dryness of the skin, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, and difficulty in micturition, as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation [see Adverse Reactions (6)].
  • In the presence of high environmental temperature heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). It should also be used cautiously in patients with fever. If symptoms occur, the drug should be discontinued and supportive measures instituted. Because of the inhibitory effect on muscarinic receptors within the autonomic nervous system, caution should be taken in patients with autonomic neuropathy.
  • Central nervous system (CNS) signs and symptoms include confusional state, disorientation, amnesia, hallucinations, dysarthria, ataxia, coma, euphoria, fatigue, insomnia, agitation and mannerisms, and inappropriate affect.
  • Psychosis and delirium have been reported in sensitive individuals (such as elderly patients and/or in patients with mental illness) given anticholinergic drugs. These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the drug.
  • BENTYL may produce drowsiness, dizziness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking BENTYL.
  • Myasthenia Gravis
  • With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis). It should not be given to patients with myasthenia gravis except to reduce adverse muscarinic effects of an anticholinesterase [see Contraindications (4)]
  • Intestinal Obstruction
  • Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful [see Contraindications (4)].
  • Rarely development of Ogilvie's syndrome (colonic pseudo-obstruction) has been reported. Ogilvie's syndrome is a clinical disorder with signs, symptoms, and radiographic appearance of an acute large bowel obstruction but with no evidence of distal colonic obstruction
  • Toxic Dilatation of Intestinemegacolon
  • Toxic dilatation of intestine and intestinal perforation is possible when anticholinergic agents are administered in patients with Salmonella dysentery.
  • Ulcerative Colitis
  • Caution should be taken in patients with ulcerative colitis. Large doses may suppress intestinal motility to the point of producing a paralytic ileus and the use of this drug may precipitate or aggravate the serious complication of toxic megacolon [see Adverse Reactions (6.3)]. BENTYL is contraindicated in patients with severe ulcerative colitis [see Contraindications (4)].
  • Prostatic Hypertrophy
  • BENTYL should be used with caution in patients with known or suspected prostatic enlargement, in whom prostatic enlargement may lead to urinary retention [see Adverse Reactions (6.3)]
  • Hepatic and Renal Disease
  • BENTYL should be used with caution in patients with known hepatic and renal impairment.
  • Geriatric Population
  • Dicyclomine hydrochloride should be used with caution in elderly who may be more susceptible to its adverse effects.


|clinicalTrials=

  • Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • The data described below reflect exposure in controlled clinical trials involving over 100 patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg four times a day)
  • In these trials most of the side effects were typically anticholinergic in nature and were reported by 61% of the patients. Table 1 presents adverse reactions (MedDRA 13.0 preferred terms) by decreasing order of frequency in a side-by-side comparison with placebo.


|postmarketing=

There is limited information regarding Postmarketing Experience of Dicyclomine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|drugInteractions=

  • Drug
  • Description


|useInPregnancyFDA=

  • Pregnancy Category

|useInPregnancyAUS=

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dicyclomine in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Dicyclomine during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Dicyclomine with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Dicyclomine with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Dicyclomine with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Dicyclomine with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Dicyclomine with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Dicyclomine in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Dicyclomine in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Dicyclomine in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Dicyclomine in patients who are immunocompromised.


|administration=

  • Oral
  • Intravenous

|monitoring=

There is limited information regarding Monitoring of Dicyclomine in the drug label.

  • Description


|IVCompat=

There is limited information regarding IV Compatibility of Dicyclomine in the drug label.


|overdose=

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Dicyclomine in the drug label.


|drugBox=



|mechAction=


|structure=

This image is provided by the National Library of Medicine.


|PD=

There is limited information regarding Pharmacodynamics of Dicyclomine in the drug label.


|PK=

There is limited information regarding Pharmacokinetics of Dicyclomine in the drug label.


|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Dicyclomine in the drug label.


|clinicalStudies=

There is limited information regarding Clinical Studies of Dicyclomine in the drug label.


|howSupplied=


|fdaPatientInfo=

There is limited information regarding Patient Counseling Information of Dicyclomine in the drug label.


|alcohol=

  • Alcohol-Dicyclomine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


|brandNames=


|lookAlike=


|drugShortage= }}


{{#subobject: 

 |Page Name=Dicyclomine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Dicyclomine
 |Label Name=Dicyclomine11.png

}}


{{#subobject: 

 |Label Page=Dicyclomine
 |Label Name=Dicyclomine11.png

}}

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Dicyclomine&oldid=1022497"